Avidity
Chriss Westphal currently serves as Executive Director and Neuromuscular Franchise Lead at Avidity Biosciences, Inc., a role held since July 2023, following previous leadership positions within the company. Prior experience includes heading Commercial Planning & Analytics at Amylyx Pharmaceuticals and various roles in commercial planning and analytics at Akcea Therapeutics. Chriss has also worked as a Senior Consultant at Simon-Kucher & Partners, providing strategic advice to life sciences clients. Educationally, Chriss earned a Ph.D. in cell biology from Yale University, with a thesis on synucleins related to neurodegenerative diseases, and a B.S. in cell biology from The University of Kansas.
This person is not in any teams
This person is not in any offices
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.